References
[1] Donahue MJ, Achten E, Cogswell PM, et al. Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease. J Cereb Blood Flow Metab. 2018. 38(9): 1391-1417.
[2] Feigin VL, Norrving B. A new paradigm for primary prevention strategy in people with elevated risk of stroke. Int J Stroke. 2014. 9(5): 624-6.
[3] Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016. 387(10015): 251-72.
[4] Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet. 2004. 363(9411): 804-13.
[5] Riina HA. Neuroendovascular surgery. J Neurosurg. 2019. 131(6): 1690-1701.
[6] Chao BH, Yan F, Hua Y, et al. Stroke prevention and control system in China: CSPPC-Stroke Program. Int J Stroke. 2020 : 1747493020913557.
[7] Haeffner-Cavaillon N, Graillot-Gak C. The use of bibliometric indicators to help peer-review assessment. Arch Immunol Ther Exp (Warsz). 2009. 57(1): 33-8.
[8] Liao J, Wang J, Liu Y, et al. The most cited articles in coronary heart disease: A bibliometric analysis between 1970 and 2015. Int J Cardiol. 2016. 222: 1049-1052.
[9] Chen C, Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS One. 2019. 14(10): e0223994.
[10] Hirsch JE. An index to quantify an individual's scientific research output. Proc Natl Acad Sci U S A. 2005. 102(46): 16569-72.
[11] Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019. 18(4): 394-405.
[12] Guan T, Ma J, Li M, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology. 2017. 89(1): 53-61.
[13] Asplund K, Eriksson M, Persson O. Country Comparisons of Human Stroke Research Since 2001 A Bibliometric Study. Stroke. 2012. 43(3): 830-+.
[14] Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China's huge and complex health-care reforms. Lancet. 2012. 379(9818): 833-42.
[15] Wu Z, Wang C, Yang X, et al. Endovascular embolization of traumatic carotid cavernous fistulas. Chin Med J (Engl). 1999. 112(5): 433-7.
[16] Yang X, Wu Z, Wang C, et al. Chinese-made electrolytic detachable coil in the embolization of a dog aneurysmal model. Chin Med J (Engl). 2000. 113(10): 921-6.
[17] Bao YH, Ling F. Classification and therapeutic modalities of spinal vascular malformations in 80 patients. Neurosurgery. 1997. 40(1): 75-81.
[18] Wang ZC, Wu ZX, et al Endovascular occlusion of intracranial aneurysms with wolfram coils made by ourselves-20 cases report. [In Chinese] Chinese Journal of Neurosurgery. 1994: 1-4,59.
[19] Liu JM, Tai YW. Application of Neuroform Stent in the Treatment of Intracranial Aneurysm. [In Chinese] ACTA Academe Medicine Sinicae.2004. 26(6): 647-650.
[20] Li YX, Li XF, Wu SC, Liu W. [Treatment of an intracranial fusiform vertebral artery aneurysm with endovas-cular stent and Guglielmi detachable coils. [In Chinese] Academic Journal of Second Military Medical University. 2000. 21(11): 1052-1054.
[21] Song DL, Leng B, Xu R, et al. Treatment of Middle to Large and Giant Cerebral Aneurysms and Arteriovenous Malformations with Onyx. [In Chinese] Chinese Journal of Clinical Neurosciences. 2003. 11(4): 383-386.
[22] Fan XY, Zhang RL, Yin Q, et al. Wingspan stent for symptomatic intracranial vertebral artery and basilar artery stenosis. Chinese Journal of Cerebrovascular Diseases. [In Chinese] 2007. 4(6): 277-279,286.
[23] Yang P, Zhang Y, Zhang L, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med. 2020. 382(21): 1981-1993.
[24] Writing Group for the BASILAR Group, Zi W, Qiu Z, et al. Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry. JAMA Neurol. 2020. 77(5): 561-573.
[25] Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. 2020. 19(2): 115-122.
[26] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019. 394(10204): 1145-1158.
[27] Wang B, Cao W, Biswal S, Doré S. Carbon monoxide-activated Nrf2 pathway leads to protection against permanent focal cerebral ischemia. Stroke. 2011. 42(9): 2605-10.
[28] Wang Y, Xiao G, He S, et al. Protection against acute cerebral ischemia/reperfusion injury by QiShenYiQi via neuroinflammatory network mobilization. Biomed Pharmacother. 2020. 125: 109945.
[29] Fu DL, Li JH, Shi YH, Zhang XL, Lin Y, Zheng GQ. Sanhua Decoction, a Classic Herbal Prescription, Exerts Neuroprotection Through Regulating Phosphorylated Tau Level and Promoting Adult Endogenous Neurogenesis After Cerebral Ischemia/Reperfusion Injury. Front Physiol. 2020. 11: 57.
[30] Campbell B, Khatri P. Stroke. Lancet. 2020. 396(10244): 129-142.
[31] Liu JM, Zhou Y, Li Y, et al. Parent Artery Reconstruction for Large or Giant Cerebral Aneurysms Using the Tubridge Flow Diverter: A Multicenter, Randomized, Controlled Clinical Trial (PARAT). AJNR Am J Neuroradiol. 2018. 39(5): 807-816.
[32] Gandhi D, Chen J, Pearl M, Huang J, Gemmete JJ, Kathuria S. Intracranial dural arteriovenous fistulas: classification, imaging findings, and treatment. AJNR Am J Neuroradiol. 2012. 33(6): 1007-13.